Evommune (EVMN) Net Income towards Common Stockholders (2024 - 2026)

Evommune (EVMN) has reported Net Income towards Common Stockholders for 3 consecutive years, with -$113.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 677.38% year-over-year to -$113.6 million; the TTM figure through Mar 2026 stood at -$169.0 million (changed N/A YoY), while the FY2025 annual figure was -$132.3 million, down 95.72% from the prior year.
• Net Income towards Common Stockholders retreated to -$113.6 million in Q1 2026 per EVMN's latest filing, from -$28.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$12.5 million in Q3 2025 and bottomed at -$113.6 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$34.3 million across 3 years, with a median of -$18.3 million in 2024.
• Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders gained 21.62% — and 2026, when it plunged 677.38%.
• Evommune's Net Income towards Common Stockholders stood at -$20.7 million in 2024, then sank by 36.16% to -$28.2 million in 2025, then plunged by 302.57% to -$113.6 million in 2026.
• Business Quant data shows EVMN's Net Income towards Common Stockholders at -$113.6 million in Q1 2026, -$28.2 million in Q4 2025, and -$12.5 million in Q3 2025.